

C-Path Appoints Renowned Harvard Health Economist Amitabh Chandra to Board of Directors

TUCSON, Ariz., February 25, 2026 — Critical Path Institute® (C-Path) today announced the appointment of Amitabh Chandra, Ph.D., to its Board of Directors. Professor Chandra brings decades of expertise in health economics, policy and biopharmaceutical innovation to the C-Path leadership team. His appointment reinforces the organization's commitment to integrating rigorous economic analysis with regulatory science to accelerate drug development.

Dr. Chandra serves as the Ethel Zimmerman Wiener Professor of Public Policy and Director of Health Policy Research at the Harvard Kennedy School of Government. He is also the Henry and Allison McCance Family Professor of Business Administration at Harvard Business School. His research focuses on innovation and pricing in the biopharmaceutical industry, value in healthcare and medical malpractice.



Amitabh Chandra, Ph.D.

“Amitabh is a visionary thought leader whose work sits at the critical intersection of economics, policy and healthcare delivery,” said M. Wainwright Fishburn, J.D., chairman of the board at C-Path. “His deep understanding of capital allocation in the biopharmaceutical industry will provide invaluable perspective as we continue to build global collaborations that de-risk decision-making in drug development.”

In addition to his academic roles, Dr. Chandra is the faculty chair of the joint MS/MBA program in the life sciences at Harvard. He served on the Congressional Budget Office's Panel of Health Advisors and is an elected member of the National Academy of Medicine and the American Academy of Arts and Sciences. His work has supported key initiatives for the National Institute on Aging and the Robert Wood Johnson Foundation.

“We are operating in an era where the economic viability of medical innovation might be as crucial as the scientific discovery itself,” said C-Path CEO Klaus Romero, M.D., M.S., FCP. “Amitabh brings a rigorous framework for understanding how policy affects the speed and availability of new therapies. His guidance will help us ensure that our regulatory solutions create value for patients and the broader health ecosystem.”

“I have long admired C-Path's unique ability to bring competitors and regulators to the same table to solve shared challenges,” said Dr. Chandra. “The work C-Path does to generate consensus on new methodologies is essential for the future of medicine. I look forward to working with the board and the executive team to further this mission and help speed the delivery of safe and effective therapies to the people who need them.”

The appointment is effective immediately.

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private

partnership in response to the FDA's Critical Path Initiative. C-Path's mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 56% funded by the FDA/HHS, totaling \$23,740,424, and 44% funded by non-government source(s), totaling \$18,881,611. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.